


Personalized Prognostics: Can Genomic Testing Improve Your Melanoma Management?

The publication of this infographic was supported by Castle Biosciences.


Dermatol AMJ. 2025; <https://doi.org/10.33590/dermatolamj/YPJV3422>

What is DecisionDx-Melanoma (31-GEP)?




Clinical utility of 31-GEP assay


Implementation of 31-GEP testing ensures that high-risk patients receive appropriate care.



Implementation of 31-GEP testing improves patient outcomes.



Routine imaging guided by 31-GEP results in earlier detection of melanoma.¹⁵



What makes 31-GEP testing unique?

1 Extensive independent validation

It is one of the most validated melanoma prognostic tests, supported by:^{1,3,9,16}

- >50 peer-reviewed studies
- Data from over 10,000 patients

2 Comprehensive, actionable risk prediction

The independently validated 31-GEP score is integrated with clinicopathologic features through two proprietary algorithms to inform:


- **SLN positivity** (i31-SLNB): 31-GEP score combined with age, ulceration, Breslow thickness, and mitotic rate^{11,17}
- **Risk of recurrence** (i31-ROR): 31-GEP score combined with age, ulceration, Breslow thickness, mitotic rate, SLN status, and tumor location^{2,18}

3 Proven clinical impact

It is the only melanoma test associated with improved patient survival:^{6,16}

- MSS^{4,7,8}
- RFS^{4,7,8}
- DMFS^{4,7,8}
- OS^{6,11}

Key Takeaways



References

- Ferris LK et al. J Am Acad Dermatol. 2017;76(5):818-25.e3.
- Jarell A et al. J Am Acad Dermatol. 2022;87(6):1312-20.
- Hsueh EC et al. JCO Precis Oncol. 2021;5:PO.20.00119.
- Gastman BR et al. J Am Acad Dermatol. 2019;80(1):149-57.e4.
- Gerami P et al. J Am Acad Dermatol. 2015;72(5):780-5.e3.
- Bailey CN et al. JCO Precis Oncol. 2023;7:e2300044.
- Zager JS et al. BMC Cancer. 2018;18(1):130.
- Jarell A et al. Future Oncol. 2021;17(36):5023-31.
- Farberg AS et al. Dermatol Ther (Heidelb). 2022;12(4):807-23.
- Mulder EEAP et al. Br J Dermatol. 2021;184(5):944-51.
- Whitman ED et al. JCO Precis Oncol. 2021;5:PO.21.00162.
- Glazer et al. J of Skin. 2022;6:474-81.
- Guenther JM et al. World J Surg Oncol. 2025;23(1):5.
- Guenther JM et al. (In press). A prospective, multicenter analysis of recurrence-free survival after sentinel lymph node biopsy decisions influenced by the 31-GEP. Cancer Medicine.
- Dhillon S et al. Arch Dermatol Res. 2023;315(8):2295-302.
- Durgham RA et al. Cancers (Basel). 2024;16(21):3714.
- Tassavor M et al. Anticancer Res. 2023;43(10):4511-6.
- Pariser D et al. SKIN J Cutan Med. 2024;8(2):s386.

Abbreviations

31-GEP: 31-gene expression profile; AJCC: American Joint Committee on Cancer; DMFS: distant metastasis-free survival; GEP: genomic expression profile; i31-ROR: integrated 31 risk of recurrence; MSS: melanoma-specific survival; OS: overall survival; RFS: recurrence-free survival; SLN: sentinel lymph node; SLNB: sentinel lymph node biopsy.